Exclusive Summary

• As the absolute first-line essential medicine for over 500 million diabetic patients globally, the product has massive daily demand and zero patent barriers, enabling immediate market penetration for distributors.
• The 0.25g (250mg) formulation offers a differentiated clinical edge, perfectly suited for initial dose titration in elderly or GI-sensitive patients to minimize gastrointestinal adverse effects.
• Leveraging China's strong, vertically integrated supply chain, the product boasts outstanding cost leadership, guaranteeing competitive pricing and high profit margins for overseas distribution partners.
• Supported by stringent quality consistency standards and rich regulatory experience, the supplier can provide comprehensive CTD dossiers to facilitate fast-track registration in lucrative emerging markets.